NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity

Chimeric antigen receptor (CAR) T cells hold promise for the treatment of acute myeloid leukemia (AML), but optimal targets remain to be defined. We demonstrate that CD93 CAR T cells engineered from a novel humanized CD93-specific binder potently kill AML in vitro and in vivo but spare hematopoietic...

Descripción completa

Detalles Bibliográficos
Autores principales: Richards, Rebecca M., Zhao, Feifei, Freitas, Katherine A., Parker, Kevin R., Xu, Peng, Fan, Amy, Sotillo, Elena, Daugaard, Mads, Oo, Htoo Zarni, Liu, Jie, Hong, Wan-Jen, Sorensen, Poul H., Chang, Howard Y., Satpathy, Ansuman T., Majzner, Robbie G., Majeti, Ravindra, Mackall, Crystal L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580619/
https://www.ncbi.nlm.nih.gov/pubmed/34778803
http://dx.doi.org/10.1158/2643-3230.BCD-20-0208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580619/
https://www.ncbi.nlm.nih.gov/pubmed/34778803
http://dx.doi.org/10.1158/2643-3230.BCD-20-0208

Ejemplares similares